Organisation paid for research Program year 2025 Source: CMS Open Payments

Accellacare Hickory

Neither a doctor nor a teaching hospital

Research payments

$140,173

46 payments

Through program year 2025, Accellacare Hickory is reported as receiving $140,173 in research payments, across 46 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$13,946	34
2024	Research	$606	3
2023	Research	$1,058	4
2022	Research	$124,303	4
2021	Research	$261	1

Breakdown

Who paid Research payments · program years 2021–2025

OraSure Technologies Inc. $124,471 4 payments
Pfizer Inc. $15,703 42 payments

Studies the money was for Research payments · program years 2021–2025

InteliSwab COVID-19 Rapid Test Clinical Evaluation Study in Asymptomatic Individuals $124,471 4 payments
A Phase 3 Randomized Doubleblind Placebocontrolled Clinical Study Evaluating the Safety Tolerability Immunogenicity and Efficacy of A Variantadapted Bnt162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age $9,234 22 payments
A Phase 3 Placebocontrolled Doubleblinded Randomized Study to Evaluate the Efficacy Safety and Tolerability of A Clostridioides Difficile Vaccine in Adults 65 Years of Age and Older $4,712 12 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $856 5 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $404 1 payment
A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $404 1 payment
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $93 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.